Do analysts prefer BNR or BYSI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor BNR or BYSI?

In the previous week, Burning Rock Biotech and Burning Rock Biotech both had 1 articles in the media. Burning Rock Biotech's average media sentiment score of 0.00 equaled BeyondSpring'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Burning Rock Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BeyondSpring 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BYSI or CBUS?

Cibus has a consensus price target of $9.00, indicating a potential upside of 459.01%. Given Cibus' stronger consensus rating and higher probable upside, analysts clearly believe Cibus is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cibus 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BYSI or CBUS more profitable?

BeyondSpring has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. BeyondSpring's return on equity of 0.00% beat Cibus' return on equity. Company Net Margins Return on Equity Return on Assets BeyondSpring N/A N/A -28.88% Cibus -2,258.89% -287.03% -27.99%

Does the media prefer BYSI or CBUS?

In the previous week, BeyondSpring and BeyondSpring both had 1 articles in the media. Cibus' average media sentiment score of 0.36 beat BeyondSpring's score of 0.00 indicating that Cibus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeyondSpring 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cibus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer INO or BYSI?

Inovio Pharmaceuticals presently has a consensus target price of $3.17, indicating a potential upside of 155.38%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Inovio Pharmaceuticals is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inovio Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is INO or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat Inovio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Inovio Pharmaceuticals N/A -669.94% -73.97% BeyondSpring N/A N/A -28.88%

Does the media prefer INO or BYSI?

In the previous week, Inovio Pharmaceuticals had 2 more articles in the media than BeyondSpring. MarketBeat recorded 3 mentions for Inovio Pharmaceuticals and 1 mentions for BeyondSpring. Inovio Pharmaceuticals' average media sentiment score of 0.64 beat BeyondSpring's score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inovio Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeyondSpring 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BYSI or OKUR?

OnKure Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 493.22%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe OnKure Therapeutics is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 OnKure Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is BYSI or OKUR more profitable?

BeyondSpring's return on equity of 0.00% beat OnKure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets BeyondSpring N/A N/A -28.88% OnKure Therapeutics N/A -49.01% -45.77%

Do analysts rate PMN or BYSI?

Promis Neurosciences currently has a consensus price target of $34.00, suggesting a potential upside of 142.68%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, analysts clearly believe Promis Neurosciences is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Promis Neurosciences 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.88 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PMN or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Promis Neurosciences N/A -143.09% -109.15% BeyondSpring N/A N/A -28.88%

BeyondSpring (BYSI) Competitors

$0.75 +0.04 (+5.78%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.75 0.00 (-0.11%)

As of 09/18/2026 06:48 PM Eastern

Compare

BYSI vs. BNR, CBUS, INO, OKUR, and PMN

Should you buy BeyondSpring stock or one of its competitors? BeyondSpring's main competitors and comparable companies include Burning Rock Biotech (BNR), Cibus (CBUS), Inovio Pharmaceuticals (INO), OnKure Therapeutics (OKUR), and Promis Neurosciences (PMN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BeyondSpring compare to Burning Rock Biotech?

Burning Rock Biotech (NASDAQ:BNR) and BeyondSpring (NASDAQ:BYSI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

In the previous week, Burning Rock Biotech and Burning Rock Biotech both had 1 articles in the media. Burning Rock Biotech's average media sentiment score of 0.00 equaled BeyondSpring'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Burning Rock Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeyondSpring	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Burning Rock Biotech has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.06, meaning that its stock price is 94% less volatile than the broader market.

BeyondSpring has lower revenue, but higher earnings than Burning Rock Biotech. Burning Rock Biotech is trading at a lower price-to-earnings ratio than BeyondSpring, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.94	-$7.92M	-$0.87	N/A
BeyondSpring	$1.75M	17.62	-$1.01M	-$0.12	N/A

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by company insiders. Comparatively, 29.3% of BeyondSpring shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

BeyondSpring has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -13.60%. BeyondSpring's return on equity of 0.00% beat Burning Rock Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-13.60%	-12.98%	-8.59%
BeyondSpring	N/A	N/A	-28.88%

Summary

BeyondSpring beats Burning Rock Biotech on 7 of the 11 factors compared between the two stocks.

How does BeyondSpring compare to Cibus?

BeyondSpring (NASDAQ:BYSI) and Cibus (NASDAQ:CBUS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

Cibus has a consensus price target of $9.00, indicating a potential upside of 459.01%. Given Cibus' stronger consensus rating and higher probable upside, analysts clearly believe Cibus is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, BeyondSpring and BeyondSpring both had 1 articles in the media. Cibus' average media sentiment score of 0.36 beat BeyondSpring's score of 0.00 indicating that Cibus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeyondSpring	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cibus	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

40.3% of BeyondSpring shares are held by institutional investors. Comparatively, 33.8% of Cibus shares are held by institutional investors. 29.3% of BeyondSpring shares are held by insiders. Comparatively, 29.9% of Cibus shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

BeyondSpring has higher earnings, but lower revenue than Cibus. BeyondSpring is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	17.62	-$1.01M	-$0.12	N/A
Cibus	$3.64M	33.81	-$127.08M	-$1.65	N/A

BeyondSpring has a beta of 0.06, meaning that its stock price is 94% less volatile than the broader market. Comparatively, Cibus has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market.

BeyondSpring has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. BeyondSpring's return on equity of 0.00% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-28.88%
Cibus	-2,258.89%	-287.03%	-27.99%

Summary

Cibus beats BeyondSpring on 10 of the 15 factors compared between the two stocks.

How does BeyondSpring compare to Inovio Pharmaceuticals?

Inovio Pharmaceuticals (NASDAQ:INO) and BeyondSpring (NASDAQ:BYSI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 1.7% of Inovio Pharmaceuticals shares are owned by company insiders. Comparatively, 29.3% of BeyondSpring shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

BeyondSpring has higher revenue and earnings than Inovio Pharmaceuticals. BeyondSpring is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	2,136.93	-$84.95M	-$0.91	N/A
BeyondSpring	$1.75M	17.62	-$1.01M	-$0.12	N/A

Inovio Pharmaceuticals presently has a consensus target price of $3.17, indicating a potential upside of 155.38%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Inovio Pharmaceuticals is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BeyondSpring's return on equity of 0.00% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%
BeyondSpring	N/A	N/A	-28.88%

In the previous week, Inovio Pharmaceuticals had 2 more articles in the media than BeyondSpring. MarketBeat recorded 3 mentions for Inovio Pharmaceuticals and 1 mentions for BeyondSpring. Inovio Pharmaceuticals' average media sentiment score of 0.64 beat BeyondSpring's score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeyondSpring	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inovio Pharmaceuticals has a beta of 1.63, suggesting that its stock price is 63% more volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.06, suggesting that its stock price is 94% less volatile than the broader market.

Summary

Inovio Pharmaceuticals beats BeyondSpring on 9 of the 16 factors compared between the two stocks.

How does BeyondSpring compare to OnKure Therapeutics?

BeyondSpring (NASDAQ:BYSI) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

BeyondSpring's return on equity of 0.00% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-28.88%
OnKure Therapeutics	N/A	-49.01%	-45.77%

In the previous week, BeyondSpring had 1 more articles in the media than OnKure Therapeutics. MarketBeat recorded 1 mentions for BeyondSpring and 0 mentions for OnKure Therapeutics. BeyondSpring's average media sentiment score of 0.00 equaled OnKure Therapeutics'average media sentiment score.

Company	Overall Sentiment
BeyondSpring	Neutral
OnKure Therapeutics	Neutral

OnKure Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 493.22%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe OnKure Therapeutics is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

BeyondSpring has higher revenue and earnings than OnKure Therapeutics. BeyondSpring is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	17.62	-$1.01M	-$0.12	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A

40.3% of BeyondSpring shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 29.3% of BeyondSpring shares are held by insiders. Comparatively, 2.2% of OnKure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BeyondSpring has a beta of 0.06, suggesting that its share price is 94% less volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market.

Summary

BeyondSpring beats OnKure Therapeutics on 7 of the 13 factors compared between the two stocks.

How does BeyondSpring compare to Promis Neurosciences?

Promis Neurosciences (NASDAQ:PMN) and BeyondSpring (NASDAQ:BYSI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

BeyondSpring has higher revenue and earnings than Promis Neurosciences. BeyondSpring is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Promis Neurosciences	N/A	N/A	-$39.72M	-$8.54	N/A
BeyondSpring	$1.75M	17.62	-$1.01M	-$0.12	N/A

Promis Neurosciences currently has a consensus price target of $34.00, suggesting a potential upside of 142.68%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, analysts clearly believe Promis Neurosciences is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

50.1% of Promis Neurosciences shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 1.5% of Promis Neurosciences shares are owned by insiders. Comparatively, 29.3% of BeyondSpring shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

BeyondSpring's return on equity of 0.00% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Promis Neurosciences	N/A	-143.09%	-109.15%
BeyondSpring	N/A	N/A	-28.88%

In the previous week, BeyondSpring had 1 more articles in the media than Promis Neurosciences. MarketBeat recorded 1 mentions for BeyondSpring and 0 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.00 equaled BeyondSpring'saverage media sentiment score.

Company	Overall Sentiment
Promis Neurosciences	Neutral
BeyondSpring	Neutral

Promis Neurosciences has a beta of -0.24, suggesting that its share price is 124% less volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.06, suggesting that its share price is 94% less volatile than the broader market.

Summary

BeyondSpring beats Promis Neurosciences on 8 of the 14 factors compared between the two stocks.

Get BeyondSpring News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BYSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BYSI vs. The Competition

Export

Metric	BeyondSpring	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$30.83M	$3.88B	$7.24B	$12.95B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	-6.25	14.23	275.49	25.40
Price / Sales	17.62	1,439.65	644.37	87.46
Price / Cash	6.60	108.90	76.25	51.42
Price / Book	-1.27	15.45	10.46	6.33
Net Income	-$1.01M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-1.86%	-1.21%	0.59%	1.12%
1 Month Performance	4.12%	-3.29%	-1.74%	-2.39%
1 Year Performance	-60.95%	37.74%	18.13%	5.35%

BeyondSpring Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BYSI BeyondSpring	0.1043 of 5 stars	$0.75 +5.8%	N/A	-60.9%	$30.83M	$1.75M	N/A	44	News Coverage
BNR Burning Rock Biotech	0.6251 of 5 stars	$12.52 +7.2%	N/A	+66.1%	$122.85M	$77.16M	N/A	667
CBUS Cibus	1.5419 of 5 stars	$1.51 -4.4%	$9.00 +496.0%	+13.4%	$120.76M	$3.64M	N/A	118	News Coverage Analyst Downgrade
INO Inovio Pharmaceuticals	3.0791 of 5 stars	$1.15 -0.9%	$3.17 +175.4%	-46.1%	$119.94M	$60K	N/A	112	News Coverage
OKUR OnKure Therapeutics	2.3531 of 5 stars	$2.88 -1.7%	$17.50 +507.6%	+14.8%	$118.36M	N/A	N/A	45	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BYSI) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BeyondSpring (BYSI) Competitors

BYSI vs. BNR, CBUS, INO, OKUR, and PMN

How does BeyondSpring compare to Burning Rock Biotech?

Summary

How does BeyondSpring compare to Cibus?

Summary

How does BeyondSpring compare to Inovio Pharmaceuticals?

Summary

How does BeyondSpring compare to OnKure Therapeutics?

Summary

How does BeyondSpring compare to Promis Neurosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI vs. The Competition

BeyondSpring Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BeyondSpring (BYSI) Competitors

BYSI vs. BNR, CBUS, INO, OKUR, and PMN

How does BeyondSpring compare to Burning Rock Biotech?

Does the media favor BNR or BYSI?

Do analysts prefer BNR or BYSI?

Which has more volatility & risk, BNR or BYSI?

Which has higher valuation & earnings, BNR or BYSI?

Do insiders and institutionals hold more shares of BNR or BYSI?

Is BNR or BYSI more profitable?

Summary

How does BeyondSpring compare to Cibus?

Do analysts rate BYSI or CBUS?

Does the media prefer BYSI or CBUS?

Do institutionals and insiders hold more shares of BYSI or CBUS?

Which has better earnings and valuation, BYSI or CBUS?

Which has more volatility & risk, BYSI or CBUS?

Is BYSI or CBUS more profitable?

Summary

How does BeyondSpring compare to Inovio Pharmaceuticals?

Do insiders and institutionals believe in INO or BYSI?

Which has preferable valuation & earnings, INO or BYSI?

Do analysts prefer INO or BYSI?

Is INO or BYSI more profitable?

Does the media prefer INO or BYSI?

Which has more risk & volatility, INO or BYSI?

Summary

How does BeyondSpring compare to OnKure Therapeutics?

Is BYSI or OKUR more profitable?

Does the media refer more to BYSI or OKUR?

Do analysts recommend BYSI or OKUR?

Which has higher earnings & valuation, BYSI or OKUR?

Do insiders and institutionals hold more shares of BYSI or OKUR?

Which has more risk and volatility, BYSI or OKUR?

Summary

How does BeyondSpring compare to Promis Neurosciences?

Which has stronger earnings and valuation, PMN or BYSI?

Do analysts rate PMN or BYSI?

Do institutionals and insiders have more ownership in PMN or BYSI?

Is PMN or BYSI more profitable?

Does the media prefer PMN or BYSI?

Which has more risk and volatility, PMN or BYSI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI vs. The Competition

BeyondSpring Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools